Bashar Saad, MD
Endocrinology, Diabetes & Metabolism · San Dimas, CANPI 1275611360
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,660 of the $123,119 with a category attached, or 67.1%. 59 manufacturers reported payments, led by Boehringer Ingelheim at 38.8% of the total. Reporting peaked in 2019 at $43,403 and has fallen 80.7% since, to $8,361 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,218 payments — averaging $55.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$48K
- Lilly USA, LLC$23K
- Sanofi-aventis U.S. LLC$16K
- Johnson & Johnson$8K
- Amgen$4K
- Novo Nordisk$3K
- plus $21K from 53 others
What the payments were for
- Consulting fees$4880%
- Speaking & faculty fees$82,66067%
- Travel & lodging$3,2443%
- Food & beverage$36,35630%
- Education$3120%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$65,716
- TOUJEO$8,105
- INVOKANA$7,523
- SOLIQUA 100/33$6,479
- FREESTYLE LIBRE 3$416
- EVENITY$390
- CeQur Simplicity$346
- AFREZZA$253
- Wegovy$245
- Prolia$239
- ISTURISA$222
- MAKO$161
- MINIMED 780G$126
- UNITY DIABETES MANAGEMENT SYSTEM$123
- MOUNJARO$112
- UBRELVY$103
- DEXCOM G6 TRANSMITTER$101
How this compares
$123,119 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 2,138 | $2,352,797 |
| JardianceEmpagliflozin | 1,696 | $1,539,968 |
| MounjaroTirzepatide | 734 | $899,343 |
| TrulicityDulaglutide | 460 | $523,722 |
| RybelsusSemaglutide | 323 | $475,447 |
| ProliaDenosumab | 226 | $377,255 |
| FarxigaDapagliflozin Propanediol | 371 | $325,816 |
| JanuviaSitagliptin Phosphate | 302 | $259,795 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 266 | $188,453 |
| Tresiba Flextouch U-100Insulin Degludec | 278 | $143,325 |
| Humalog Kwikpen U-100Insulin Lispro | 558 | $114,727 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 179 | $107,217 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 757 | $86,527 |
| Tresiba Flextouch U-200Insulin Degludec | 119 | $82,799 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 199 | $79,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $3,470 | $2,828,2442,461 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $47,810 | $1,666,6221,850 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $23,040 | $1,453,6791,345 claims |
| AmgenProlia, Evenity (2 Syringes) | $3,904 | $410,292240 claims |
| AstraZenecaFarxiga | $946 | $325,816371 claims |
| MerckJanuvia, Janumet | $102 | $311,014359 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15,942 | $48,49241 claims |
| Mannkind CorporationAfrezza | $2,759 | $41,95932 claims |
| AbbVieSynthroid | $562 | $28,118368 claims |
| BayerKerendia | $491 | $24,62225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Dimas
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.